NeoGenomics Inc. (Nasdaq: NEO)

https://www.neogenomics.com

LinkedIn: https://www.linkedin.com/company/neogenomics-laboratories

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. *

	Start	2017-03-13 renamed before
	Group	NeoGenomics (Group)
	Predecessor	NeoGenomics Laboratories Inc.
	Industry	diagnostic services
	Industry 2	cancer test, classfication
	Person	VanOort, Douglas (NeoGenomics 201703 CEO)

	Street	12701 Commonwealth Drive Suite 9
	City	33913 Fort Myers, FL
	Tel	+1-239-768-0600
		Address record changed: 2024-01-05

Basic data	Employees	F: 1,001 to 5,000 (2021-12-31)
	Currency	USD
	Annual sales	484,329,000 (revenue, net, total, consolidated (2021) 2021-12-31)
	Profit	-8,347,000 (2021-12-31)
	Cash	316,827,000 (2021-12-31)

		* Document for »About Section«: NeoGenomics, Inc.. (5/9/22). "Press Release: NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary". Ft. Myers, FL.

		Record changed: 2023-07-10

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for NeoGenomics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)